Draft Guidance on Erythromycin

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

**Active Ingredient:** Erythromycin

**Dosage Form; Route:** Gel; topical

**Recommended Studies:** Acceptable comparative physicochemical characterization of the test and reference standard (RS) formulations of the product to establish that the test product is pharmaceutically equivalent to the RS with the identical strength

**Analytes to measure (in appropriate biological fluid):** Not Applicable

**Bioequivalence based on (90% CI):** Not applicable

**Waiver request of in vivo testing:** Not Applicable

**Dissolution test method and sampling times:** Not Applicable